Clinical evidence from the DELIVER trial and other studies shows that SGLT2 inhibitors present valuable benefits for HFpEF and mid-range ejection fraction (HFmrEF with LVEF ranging from 40 to 49%) patients, which contributed to their introduction into current HF management guidelines[13,14]. Here, SLC5A2 is linked to hydrops fetalis.